TSC2 Antibody, Biotin conjugated

Code CSB-PA343033LD01HU
Size US$299
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Full Product Name Rabbit anti-Homo sapiens (Human) TSC2 Polyclonal antibody
Uniprot No. P49815
Target Names TSC2
Alternative Names FLJ43106 antibody; LAM antibody; OTTHUMP00000158940 antibody; OTTHUMP00000198394 antibody; OTTHUMP00000198395 antibody; PPP1R160 antibody; Protein phosphatase 1; regulatory subunit 160 antibody; TSC complex subunit 2 antibody; tsc2 antibody; TSC2_HUMAN antibody; TSC4 antibody; TSC4 gene; formerly antibody; TSC4; formerly antibody; Tuberin antibody; Tuberous sclerosis 2 antibody; Tuberous sclerosis 2 protein antibody; Tuberous sclerosis 2 protein homolog antibody
Raised in Rabbit
Species Reactivity Human
Immunogen Recombinant Human Tuberin protein (1396-1496AA)
Immunogen Species Homo sapiens (Human)
Conjugate Biotin
Clonality Polyclonal
Isotype IgG
Purification Method >95%, Protein G purified
Concentration It differs from different batches. Please contact us to confirm it.
Buffer Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form Liquid
Tested Applications ELISA
Protocols ELISA Protocol
Troubleshooting and FAQs Antibody FAQs
Storage Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.

Target Data

Function In complex with TSC1, this tumor suppressor inhibits the nutrient-mediated or growth factor-stimulated phosphorylation of S6K1 and EIF4EBP1 by negatively regulating mTORC1 signaling. Acts as a GTPase-activating protein (GAP) for the small GTPase RHEB, a direct activator of the protein kinase activity of mTORC1. May also play a role in microtubule-mediated protein transport. Also stimulates the intrinsic GTPase activity of the Ras-related proteins RAP1A and RAB5.
Gene References into Functions
  1. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells. PMID: 29758070
  2. This study demonstrated that the TSC2 mutation related the cerebellar abnormalities in tuberous sclerosis complex. PMID: 29882962
  3. a novel TSC2 mutation is a cause of mild tuberous sclerosis in a family and has reduced expression PMID: 28659645
  4. Data found that TSC2 negatively regulates the expression of EP3 in an mTORC1- independent manner. PMID: 28710231
  5. Mutations in TSC2 gene on chromosome 9q34 that encode tuberin are associated with fetal Cardiac Rhabdomyoma that can be the initial finding in patients with Tuberous Sclerosis Complex. 5 known "pathogenic" TSC2-causing gene mutations were confirmed, also detected 6 "likely pathogenic" mutations. PMID: 29642139
  6. When exposed to urotensin-II, TSC2-deficient cells exhibited greater migration, anchorage-independent cell growth, and matrix invasion PMID: 27458154
  7. To the best of our knowledge, this is the first report of the c.3599G>C (p.R1200P) variant in exon 29 of the TSC2 gene related to a severe clinical course and multiple kidney transplants in a patient with tuberous sclerosis. PMID: 29308833
  8. These results demonstrate Tsc2-deficient mesenchymal progenitors cause aberrant morphogenic signals, and identify an expression signature including Lgals3 relevant for human disease of TSC1/TSC2 inactivation and mTORC1 hyperactivity. PMID: 28695825
  9. Functional validation of the oncogenic cooperativity and targeting potential of tuberous sclerosis mutation in medulloblastoma using a MYC-amplified model cell line PMID: 28409891
  10. This case provides evidence for a unique TSC2 mutation that resulted in an atypical clinical presentation and indicates potential shortcomings of the current diagnostic criteria for TSC. These findings may have implications for genetic counseling and screening. PMID: 28127866
  11. we report a pathogenic TSC2 variant, c.1864C>T, p.(Arg622Trp), associated with a mild phenotype, with most carriers meeting fewer than two major clinical diagnostic criteria for TSC. This finding has significant implications for counseling patients regarding prognosis. PMID: 28211972
  12. The results highlight a new role of TSC2 in protecting glioblastoma against photodynamic therapy-induced cell death, and TSC2 and YWHAZ as new RIP3 partners. PMID: 27984090
  13. Study provides new information regarding cerebellar lesions in tuberous sclerosis complex: cerebellar lesions are significantly much more frequent in patients with TSC2 mutations than TSC1 mutations or patients with no mutation identified, and Crus II is the most frequent location of cerebellar lesions. PMID: 28786492
  14. Two pathogenic mutations in TSC1 and one in TSC2 genes were identified in patients with tuberous sclerosis complex; the patient with TSC2 mutation manifested a more severe clinical phenotype PMID: 28288225
  15. Novel missense mutation in the exon 19 of the TSC2 gene is associated with tuberous sclerosis. PMID: 28397210
  16. Mutation in TSC2 is associated with lymphangioleiomyomatosis. PMID: 28202529
  17. Results show that tuberous sclerosis complex disease segregates with a silent substitution in TSC2, c.4149C>T, p.(Ser1838Ser), which leads to the formation of an active donor splice site, resulting in three shorter alternatively spliced transcripts with premature stop codons. PMID: 28336152
  18. Clinical whole exome sequencing of blood and tumor samples con fi rmed the diagnosis of methylmalonic acidemia and revealed two somatic inactivating mutations in TSC2, suggesting the potential consideration of an mTOR inhibitor in the event of tumor recurrence. PMID: 27748010
  19. TSC2 N-terminal lysine acetylation status affects to its stability modulating mTORC1 signaling and autophagy/cell proliferation. PMID: 27542907
  20. TSC2 mutations leading to severe tuberous sclerosis in Chinese children. PMID: 27859028
  21. These results suggested that TSC2 heterozygosity caused neurological malformations in primitive neural stem cells, indicating that its heterozygosity might be sufficient for the development of neurological abnormalities in patients. PMID: 28344003
  22. the first structural information on TSC2/tuberin with novel insight into the molecular function. PMID: 27493206
  23. Novel TSC2 mutations in Chinese patients with tuberous sclerosis. PMID: 28178598
  24. Gankyrin overexpression activates mTORC1 signaling and accelerating TSC2 degradation in colorectal tumor cells. PMID: 26975632
  25. data provide the first evidence that tuberin plays a novel role in regulating ROS generation, NADPH oxidase activity, and Nox expression that may potentially be involved in development of kidney tumor in patients with tuberous sclerosis complex PMID: 27278252
  26. Our evidence suggests that variants in TSC2 exons 25 or 31 are very unlikely to cause classical TSC, although a role for these exons in tissue/stage specific development cannot be excluded. PMID: 26703369
  27. In children with tuberous sclerosis complex, nonsense mutations in the TSC2 gene had a correlation with autistic behavior. PMID: 24698169
  28. By interfering with TSC-Rheb complex, arginine relieves allosteric inhibition of Rheb by TSC. Arginine cooperates with growth factor signaling which further promotes dissociation of TSC2 from lysosomes and activation of mTORC1. PMID: 26742086
  29. Results confirm strong association between TSC2 mutation and angiomyolipoma burden, and they indicate that everolimus response occurs regardless of mutation type or location or when no mutation in TSC1 or TSC2 has been identified. PMID: 25782670
  30. Tuberous sclerosis is a syndrome caused by dominant mutations in Tuberin (TSC2),causing Autism spectrum disorder - like behaviors, seizures, intellectual disability and characteristic brain and skin lesions. PMID: 26393489
  31. Lysosomal recruitment of TSC2 is a universal response to stimuli that inactivate mTORC1, and that the presence of any single stress is sufficient to cause TSC2 lysosomal localization. PMID: 26868506
  32. results confirm the consistent finding of TSC2 mutations in LAM samples, and highlight the benefit of laser capture microdissection and in-depth allele analyses for detection, such as NGS PMID: 26563443
  33. Data shows frequent loss of TSC2 in hepatocellular carcinoma cells (HCC) and that TSC2-null cell lines were more sensitive to mTOR inhibition by everolimus suggesting that TSC2 loss is a predictive biomarker for the response to everolimus in HCC patients. PMID: 25724664
  34. Multiple mutations in TSC2 during kidney development lead to severe phenotype of multifocal renal cell carcinoma. PMID: 25432535
  35. A short segment of chromosome 16 encodes the tumor suppressor gene tuberin as well as the protein polycystin 1, which are responsible for tuberous sclerosis complex type 2 and autosomal-dominant polycystic kidney disease type 1, respectively. PMID: 25355409
  36. A novel frame-shifting mutation c.4258-4261delTCAG in the TSC2 gene is associated with tuberous sclerosis in a Chinese family. PMID: 26252095
  37. pUL38 can activate mTORC1 in both TSC2-dependent and -independent manners. PMID: 25972538
  38. a novel frame shift Tuberous Sclerosis Complex-2 Mutation in three patients with Tuberous sclerosis complex but with different severity of symptoms PMID: 25563326
  39. these results demonstrate that TSC2-deficient cells have enhanced choline phospholipid metabolism and reveal a novel function of the TSC proteins in choline lysoglycerophospholipid metabolism PMID: 25780943
  40. This study demonstrates that TSC2-deficient tumor cells are hypersensitive to oxidative stress-dependent cell death, and provide critical proof of concept that TSC2-deficient cells can be therapeutically targeted PMID: 25185584
  41. TSC2/mTORC1 signaling contributes to the maintenance of intestinal epithelium homeostasis by regulating Notch activity. PMID: 25654764
  42. In TSC2-deficient angiomyolipoma patient cells, IRF7 is a pivotal factor in the Rheb/mTOR pathway. PMID: 25476905
  43. Studied conditions that increase the sensitivity of cancer cells to MK-2206. and found reduction by salinomycin of Akt and downregulation of pAkt, pGSk3beta, pTSC2, and p4EBP1 by cotreatment with MK-2206. PMID: 25114899
  44. The features of alpha-smooth muscle cells of a patient affected by lymphangioleiomyomatosis associated with Tuberous sclerosis complex, named LAM/TSC cells, bearing a TSC2 mutation and an epigenetic defect causing the absence of tuberin, were investigated. PMID: 24606538
  45. study describes 2 cases of genetically proven TCS2, sharing the same genotype; detected a novel, small and in frame deletion/insertion TSC2 mutation on exon 30 (c.3664_3665delinsTT-p.Asp1222Phe) PMID: 24794161
  46. This is the first mutation and multiplex ligation-dependent probe amplification (MLPA) analyses of TSC2 in Korean Angiomyolipomas that focus on tuberous sclerosis complex. PMID: 25281918
  47. This work indicates a novel role for this TSC2 gene, which encodes an activator of cell proliferation in response to androgen stimulation. PMID: 24318044
  48. TSC2 somatic second-hit mutations are associated with angiofibroma development in tuberous sclerosis. PMID: 24271014
  49. TSC2 mutations are associated with a more severe, earlier presenting tuberous sclerosis complex phenotype. PMID: 24917535
  50. Two novel gross deletions of TSC2 gene in Malay patients with tuberous sclerosis complex and TSC2/PKD1 contiguous gene deletion syndrome, respectively. PMID: 24683199
  51. TSC2 also functions as a transcription factor. PMID: 24748662
  52. oxidative stress induces Tnfaip8 l1/Oxi-beta, which results in increased autophagy by its exclusive binding with FBXW5 to stabilize TSC2 PMID: 24444419
  53. Prenatal diagnosis of an intrathoracic lesion with a family history of parental epilepsy should raise a suspicion of fetal cardiac rhabdomyoma and tuberous sclerosis. PMID: 24075384
  54. Covalent modification of TSC2 by iNOS-derived NO is associated with impaired TSC2/TSC1 dimerization, mTOR pathway activation, and proliferation of human melanoma. PMID: 24398473
  55. These data suggest that regulation of TSC2 subcellular localization may be a general mechanism to control its activity and place TSC2 in the amino-acid-sensing pathway to TORC1. PMID: 24529380
  56. An increased frequency of C>G/G>C and C>T/G>A mutations in the coding strand was found in TSC2. PMID: 23846400
  57. OPG stimulated proliferation of cells cultured from explanted LAM lungs, and selectively induced migration of lymphangioleiomyomatosis cells identified by the loss of heterozygosity for TSC2. PMID: 23867796
  58. Data show growth-inhibitory and proapoptotic effects of simvastatin on TSC2-null lymphangioleiomyomatosis cells compared with atorvastatin. PMID: 23947572
  59. Pim2 directly phosphorylates TSC2 on Ser-1798 and relieves the suppression of TSC2 on mTOR-C1, leading to multiple myeloma cells proliferation. PMID: 23818547
  60. No differences emerged in mutation distributions and types in precedent studies, excepting low frequency of the TSC2 nonsense mutation PMID: 23389244
  61. Missense mutations located in the central region of TSC2 (exons 23-33) are associated with significantly reduced incidence of infantile spasms. PMID: 22867869
  62. Our results suggest that tuberin and p27 are aberrantly expressed in malignant breast tissue PMID: 23689538
  63. Genetic investigation of the coding exons of TSC1 and TSC2 revealed a 4 bp deletion at nucleotides 3693-3696 in exon 30 of the TSC2 gene. PMID: 23217510
  64. Two novel TSC2 mutations in Chinese patients with tuberous sclerosis complex. PMID: 23254740
  65. Our results suggest that XLID CUL4B mutants are defective in promoting TSC2 degradation and positively regulating mTOR signaling in neocortical neurons. PMID: 23348097
  66. Patients with mutations in TSC2 tended to have a higher frequency of hepatic angiomyolipomas than those with mutations in TSC1 or those with no mutations detected. PMID: 22251200
  67. Patient with TSC2 1801A>G mutation was found to have five facial features of TSC, including a rash of facial angiofibromas, a shagreen patch, a forehead plaque, gingival fibromas, and dental pitting. PMID: 22707510
  68. study found tuberin and PRAS40 to be potent anti-apoptotic gatekeepers in early mammalian stem-cell differentiation; data allow new insights into the regulation of early stem-cell maintenance and differentiation and identify a new role of the tumor suppressor tuberin and the oncogenic protein PRAS40 PMID: 22090422
  69. Eighty percent of cardiac rhabdomyomas are associated with tuberous sclerosis. In this case, molecular testing for tuberous sclerosis identified two variants in the TSC2 gene. PMID: 21846442
  70. TSC2 protein-truncating mutations and small in-frame mutations are associated with distinctly different intelligence profiles, providing further evidence that different types and locations of TSC germline mutations PMID: 22189265
  71. TSC2 R1200W variant, and four other TSC2 missense variants associated with a mild TSC phenotype, confirmed that the changes disrupted the TSC1-TSC2 function. The TSC1-TSC2 interaction was not affected by the amino acid substitution. PMID: 21332470
  72. The results defined the TSC2-mTOR pathway as a key determinant in the differentiation of monocytes into M2 phenotype tumor-associated macrophages that promote angiogenesis. PMID: 22287548
  73. Tuberous sclerosis complex protein TSC2 plays a critical role in Purkinje cell survival by regulating endoplasmic reticulum and oxidative stress. PMID: 21419848
  74. ULK1 negatively regulates the kinase activity of mTORC1 and cell proliferation in a manner independent of Atg5 and TSC2 PMID: 21795849
  75. Tuberin regulates the cellular localization of cyclin B1. PMID: 21900748
  76. Mutations in TSC2 is associated with angiomyolipoma. PMID: 21949787
  77. Two females cases with typical manifestations of Tuberous sclerosis complex, horseshoe kidney, and an identical variant c.5138G>A in exon 39 (p.Arg1713His) of TSC2 gene. PMID: 21910228
  78. These findings establish a mouse model for TSC-related anxiety phenotypes and suggest that anxiety disorders in TSC have a biological foundation. PMID: 20882401
  79. This study suggested that allelic imbalances of TSC2 in nonlesional focal epileptic tissue. PMID: 21555252
  80. TSC2 binds to the death domain of DAPK. This interaction is required for TSC2 to reduce DAPK protein levels and half-life. DAPK is regulated by the lysosome pathway. Lysosome inhibition blocks TSC2-mediated degradation of DAPK. PMID: 21134130
  81. presence of TSC2 mutations, in addition to TSC1 mutations, underlines the involvement of mTOR signaling in urothelial carcinoma PMID: 21533174
  82. These findings link TACC3 to novel structural and cell division functions of TSC2. PMID: 20237422
  83. Human TSC2-null fibroblast-like cells induce hair follicle neogenesis and hamartoma morphogenesis. PMID: 21407201
  84. Functional assessment of variants in the TSC2 genes identified in individuals with Tuberous Sclerosis Complex PMID: 21309039
  85. Increased expression of tuberin in human uterine leiomyoma. PMID: 21145542
  86. study identified six TSC2 mutations, one indel, one nonsense, and four missense in pancreatic neuroendocrine tumors PMID: 21252315
  87. One of the targets of HtrA1 activity during fetal development is the TSC2-TSC1 pathway. PMID: 20671064
  88. Lymphangioleiomyomatosis (LAM), occurring sporadically (S-LAM) or in patients with tuberous sclerosis complex (TSC), results from abnormal proliferation of LAM cells exhibiting mutations or loss of heterozygosity (LOH) of the TSC genes, TSC1 or TSC2. PMID: 20639436
  89. Lymphangioleiomyomatosis is characterized by cystic lung destruction, resulting from proliferation of smooth-muscle-like cells, which have mutations in the tumor suppressor gene TSC2. PMID: 21036916
  90. A hypomorphic allele of Tsc2 highlights the role of TSC1/TSC2 in signaling to AKT and models mild human TSC2 alleles PMID: 19357198
  91. Rheb controls proliferation of TSC2-deficient cells by a mechanism that involves regulation of AMPK and p27, and that Rheb is a potential target for TSC/LAM therapy. PMID: 20818424
  92. p22(phox)-based Nox oxidases maintain HIF-2alpha protein expression through inactivation of tuberin and downstream activation of ribosomal protein S6 kinase 1/4E-BP1 pathway PMID: 20304964
  93. Tuberin-null cells become nonadherent and invasive and these nonadherent cells express cleaved forms of beta-catenin. PMID: 20042714
  94. TSC2 has a role in controlling cell polarity and migration by regulating CDC42 and RAC1 activation PMID: 20530489
  95. AMPK functions to inhibit IGF-I-stimulated PI3K pathway activation through stimulation of IRS-1 serine 794 phosphorylation. PMID: 20363874
  96. ARD1 functions as an inhibitor of the mTOR pathway and that dysregulation of the ARD1-TSC2-mTOR axis may contribute to cancer development PMID: 20145209
  97. results identify a cytoplasmic pathway for ROS-induced ATM activation of TSC2 to regulate mTORC1 signaling and autophagy, identifying an integration node for the cellular damage response PMID: 20160076
  98. In the brain, TSC2 has been implicated in cell body size, dendritic arborization, axonal outgrowth and targeting, neuronal migration, cortical lamination, and spine formation [REVIEW]. PMID: 20146692
  99. found increased MMP-2 expression in cells lacking TSC1/TSC2 compared with their respective controls PMID: 19395678
  100. Data suggest that the three mutations were most likely de novo, as parents of affected patients did not present any features of TSC. PMID: 19259131

Show More

Hide All

Involvement in disease Tuberous sclerosis 2 (TSC2); Lymphangioleiomyomatosis (LAM); Focal cortical dysplasia 2 (FCORD2)
Subcellular Location Cytoplasm, Membrane, Peripheral membrane protein
Tissue Specificity Liver, brain, heart, lymphocytes, fibroblasts, biliary epithelium, pancreas, skeletal muscle, kidney, lung and placenta.
Database Links

HGNC: 12363

OMIM: 191092

KEGG: hsa:7249

STRING: 9606.ENSP00000219476

UniGene: Hs.90303

Most popular with customers

Newsletters

Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1